Contact Information: For further information contact: David Carey Lazar Partners Ltd. 212-867-1768
Electro-Optical Sciences Expands Management Team
| Source: Electro-Optical Sciences
IRVINGTON, NY--(Marketwire - February 12, 2008) - Electro-Optical Sciences, Inc. ("EOS")
(NASDAQ : MELA ), a medical device company focused on the design and
development of MelaFind®, a non-invasive, point-of-care instrument to
assist in the early diagnosis of melanoma, today announced the appointment
of Tina Cheng-Avery to the Company's senior management team.
"Tina comes to us with over 20 years of experience in the commercialization
of dermatology products from Aveeno, Neutrogena, Elizabeth Arden, and
Pierre Fabre. Her insights into consumer behavior, the workings of the
dermatologist's office, and market preparation will be invaluable to us as
we continue pre-commercialization efforts and discussions with potential
partners for the commercialization of MelaFind," said Joseph V. Gulfo, MD,
MBA, President and CEO of Electro-Optical Sciences.
"I am thrilled to be joining EOS and working on MelaFind. It is an
important product that I am confident will resonate with both patients and
caregivers in the dermatology field," said Tina Cheng-Avery, Vice President
of Commercialization. "In my experience in dermatology, the two things that
matter most for a new product are patient demand and practice dynamics,
both of which, I believe, are very favorable for MelaFind."
Ms. Cheng-Avery joins EOS in the newly created position of Vice President
of Commercialization from Pierre Fabre Dermo-Cosmetique USA/Genesis
Pharmaceutical where she served as Vice President of Marketing and managed
the Avène and Glytone dermo-cosmetic skincare product lines distributed
through dermatologist and plastic surgeon offices.
Previously, Ms. Cheng-Avery was Global Marketing Director for Skin Care at
Elizabeth Arden, Inc. where she managed a $300 million skin care portfolio.
In addition, she led a collaboration between Elizabeth Arden and Allergen
Pharmaceuticals and was responsible for launching Prevage Anti-Aging
Treatment.
Other key positions she has held include Vice President of Marketing for
Wella Personal Care of North America, group product director at Johnson &
Johnson's Neutrogena Corporation, and Associate Brand Manager for Aveeno at
S.C. Johnson & Family, Inc.
Ms. Cheng-Avery holds a Master of Business Administration degree from
Northwestern University.
About Electro-Optical Sciences
EOS is a medical device company focused on designing and developing a
non-invasive, point-of-care instrument to assist in the early diagnosis of
melanoma. MelaFind features a hand-held imaging device that emits light of
multiple wavelengths to capture images of suspicious pigmented skin lesions
and extract data. Using sophisticated algorithms, the data are then
analyzed against a proprietary database of melanomas and benign lesions in
order to provide information to the physician and produce a recommendation
of whether the lesion should be biopsied.
Melanoma is the deadliest of skin cancers, responsible for approximately
80% of all skin cancer deaths. Unless melanoma is detected early and
excised with proper margins, the patient survival rate is poor, as there is
currently no cure for advanced stage melanoma.
For more information on EOS, visit www.eosciences.com.
Safe Harbor
This press release includes "forward-looking statements" within the meaning
of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to our plans, objectives, expectations and intentions
and other statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes" and variations of such words
or similar expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant
uncertainties and changes in circumstances, many of which are beyond our
control. There can be no assurance that our beliefs or expectations will be
achieved. Actual results may differ materially from our beliefs or
expectations due to economic, business, competitive, market and regulatory
factors.